Research Reference
Thymalin
Thymus peptide bioregulator studied for immune function
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Preclinical-Only — For Educational Purposes Only
This compound has no established human dosing. The information below documents preclinical (animal) findings and is provided for research and educational reference only. It is not medical advice or a dosing recommendation.
Thymalin is a thymus-derived peptide bioregulator studied for immune system support in preclinical research. There is no established human dosing.
Reconstitution
Thymalin is a thymus-derived peptide bioregulator complex developed in the Russian Federation and registered there. It is supplied as a lyophilized vial or pre-formulated solution for intramuscular or subcutaneous use. It is not FDA-approved in the United States.
No standardized human reconstitution protocol is established outside the CIS-region registered product. Compounded "research" forms sold online are not FDA-approved.
Cycling Protocol
Studied CIS-region protocols describe Thymalin administered in short courses (e.g., 5–10 injections over 1–2 weeks), sometimes repeated after an interval. No standardized long-term cycle is established; Thymalin is not FDA-approved and durations are community extrapolation.
Routes of Administration
Subcutaneous injection (studied route): Daily or alternate-day in short courses.
No oral route is established. Thymalin is not FDA-approved in the US.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Immune bioregulator | Thymalin + Vilon / Vladonix | Combined CIS-region immune bioregulators (community) |
Stacking combinations are community extrapolation. Thymalin is not FDA-approved.
Side Effects & Safety
- No human safety database in US frameworks — Thymalin is not FDA-approved and Western safety data is limited
- Injection-site reactions — possible
- Generally described as well-tolerated in the published CIS-region literature at studied doses
Thymalin is not FDA-approved in the United States. It is registered in some other countries. Compounded research-peptide forms are not FDA-approved.
Research Basis
Thymalin is a peptide bioregulator complex derived from thymus tissue, developed in the Russian Federation (St. Petersburg Institute of Bioregulation and Gerontology).
Mechanism: Described as a tissue-specific bioregulator supporting thymus and T-cell immune function, in the peptide-bioregulator tradition.
Clinical evidence: Published CIS-region studies describe use in immune support, post-illness recovery, and aging contexts, typically as short injection courses. Not FDA-approved in the US; Western trial data is limited.
Not FDA-approved in the US. Compounded research-peptide forms are sold for research purposes only.